Study record · MOTS-c
MOTS-MET: MOTS-c for insulin sensitivity in adults with prediabetes and overweight/obesity
Recruiting; no results posted as of this review.
Key result
Recruiting; no results posted as of this review.
Study details
Study designRandomized, double-blind, placebo-controlled clinical trial
PhasePhase 2a
PopulationAdults 18-65 with prediabetes and BMI 27-40
Sample size120 planned
RouteSubcutaneous
Regimen / exposureFixed dose once daily for 12 weeks; public registry does not state the dose
Duration12 weeks + safety follow-up to week 16
ComparatorPlacebo
Primary endpoint / questionOGTT-derived insulin sensitivity plus metabolic and safety endpoints
Safety resultSafety is a co-primary/primary focus; no public outcome data yet.
Key limitationsTrial registration proves prospective human development, not efficacy or established safety.
Registry / identifierNCT07505745